COPN — Cosmo Pharmaceuticals NV Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapMomentum Trap

Annual income statement for Cosmo Pharmaceuticals NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	65.1	102	92.8	267	104
Cost of Revenue
Gross Profit	32.1	61.6	53.4	221	50.6
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	54	74	94.7	118	107
Operating Profit	11.1	28.1	-1.88	149	-3.24
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	24	24.5	-6.49	153	-0.918
Provision for Income Taxes
Net Income After Taxes	21.7	17.5	-10.7	133	-3.49
Minority Interest
Net Income Before Extraordinary Items
Net Income	21.7	17.2	-10.8	133	-3.61
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	21.7	17.2	-10.8	133	-3.61
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.28	1.05	-0.667	8.16	-0.22
Dividends per Share